2022年11月30日

2022年11月29日TrialSpark今天宣布收购后的自由党的形成生物的多数地位从体式生物科学免疫皮肤学资产的投资组合。自由党生物管道现在包括全球权利gusacitinib,口服阶段3-ready双重JAK /麦克米兰抑制剂发展为慢性湿疹,和阶段2预备ASN008局部瘙痒钠离子通道阻滞剂在发展与过敏性皮肤炎有关。自由党生物将继续这些资产的发展,利用TrialSpark tech-enabled药物开发能力将这些疗法患者更快和更有效率。交易的财务条款没有披露。Gusacitinib有可能成为第一个口服疗法在美国批准用于治疗慢性手部湿疹(切)。在阶段2 b的一项研究中,Gusacitinib 80毫克是显示有统计学意义和潜在的临床意义的改进在初级和二级端点和耐受性良好。切是一个缺医少药条件未满足的需求高,影响到10%的成年人,没有批准治疗在美国和一些可用的标签选项。格瓦拉对生活质量有很大的负面影响,包括心理健康和劳动力生产率,可能导致一些并发症,如睡眠障碍和抑郁症。ASN008表明承诺在瘙痒疗效数据(痒)与过敏性皮肤炎有关,和是一个阶段2预备互补gusacitinib管道项目。慢性痒是过敏性皮肤炎的特征,影响超过1650万病人在美国。 ASN008 has the potential to be used in combination with other topical and systemic therapies in atopic dermatitis, as well as a meaningful opportunity to expand into other itch and pain related indications. “We are excited about the opportunity to add these important products to our portfolio of development assets,” said Dr. Gavin Corcoran, TrialSpark’s Chief Medical Officer. “Both chronic hand eczema and itch are conditions that negatively affect the lives of the patients that have them, as well as their families. An effective treatment has the potential to improve the quality of life for both.” Beyond gusacitinib and ASN008, the transaction also included a preclinical dual JAK/SYK inhibitor named ASN011. Libertas Bio is open to in-licensing additional complementary products to build a differentiated pipeline focused on immunodermatology treatments. Prior to this transaction, TrialSpark has in-licensed multiple assets, deploying capital and pursuing the development of drug programs as part of its mission to bring new treatments to patients faster and more efficiently. As part of its business development strategy, TrialSpark uses balance sheet capital to develop, acquire and/or license assets, leveraging its in-house drug development engine to run trials significantly faster and more efficiently than industry standards. TrialSpark is actively pursuing partnerships with both small biotech and larger pharma companies through flexible and creative collaboration structures, maximizing the potential value of drug candidates for all stakeholders through faster and more efficient clinical development programs. For example, the company recently partnered with global pharmaceutical company Sanofi to jointly acquire and develop novel therapies. TrialSpark is focused on clinical stage assets in rheumatology, dermatology, CNS, and cardiometabolic diseases, with a focus on chronic diseases that are treated outside of a hospital setting. About TrialSpark Founded in 2016, TrialSpark is a tech-driven pharma company differentiated by radically more efficient drug development. TrialSpark has built a technology platform that optimizes all aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies and develops them faster, unlocking greater value per program and accelerating access to new treatments for patients. TrialSpark’s current therapeutic areas of focus include rheumatology, dermatology, CNS, and cardiometabolic diseases.